Response of bone turnover markers to raloxifene treatment in postmenopausal women with osteopenia

Summary We used two methods of identifying women who reached the target for raloxifene treatment with bone turnover markers. Both approaches identified women that responded to treatment but did not fully agree and may be complementary. Introduction The change in bone turnover markers (BTMs) in respo...

Full description

Saved in:
Bibliographic Details
Published in:Osteoporosis international 2016-08, Vol.27 (8), p.2585-2592
Main Authors: Naylor, K. E., Jacques, R. M., Peel, N. F. A., Gossiel, F., Eastell, R.
Format: Article
Language:English
Subjects:
Adult
Aged
Biomarkers - blood
Bone Density
Bone diseases
Bone Diseases, Metabolic - drug therapy
Bone mineral density
Bone Remodeling
Bone turnover
Clinical medicine
Clinical trials
Collagen (type I)
Collagen Type I - blood
Endocrinology
Estrogen receptors
Female
Fractures
Hip
Hormone replacement therapy
Humans
Laboratories
Medicine
Medicine & Public Health
Metabolism
Middle Aged
Original Article
Orthopedics
Osteopenia
Osteoporosis
Osteoporosis, Postmenopausal - drug therapy
Post-menopause
Postmenopause
Procollagen
Procollagen - blood
Raloxifene
Raloxifene Hydrochloride - therapeutic use
Rheumatology
Spine
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary We used two methods of identifying women who reached the target for raloxifene treatment with bone turnover markers. Both approaches identified women that responded to treatment but did not fully agree and may be complementary. Introduction The change in bone turnover markers (BTMs) in response to osteoporosis therapy can be assessed by a decrease beyond the least significant change (LSC) or below the mean of the reference interval (RI). We compared the performance of these two approaches in women treated with raloxifene. Methods Fifty postmenopausal osteopenic women (age 51–72 years) were randomised to raloxifene or no treatment for 2 years. Blood samples were collected for the measurement of BTM. The LSC for each marker was calculated from the untreated women and the RI obtained from healthy premenopausal women (age 35–40 years). Bone mineral density (BMD) was measured at the spine and hip. Results There was a decrease in BTM in response to raloxifene treatment, percentage change at 12 weeks: C terminal telopeptide of type I collagen (CTX) −39 % (95 % CI −48 to −28) and N terminal propeptide of type I procollagen (PINP) −32 % (95 % CI −40 to −23) P  
ISSN:0937-941X
1433-2965
DOI:10.1007/s00198-016-3573-z